Sign in
Not yet recruitingPhase 1

Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge)

Key facts

Who runs it
Leiden University Medical Center
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 1
People taking part
14 people, planned
Started
1 Mar 2025
Planned end
30 Sept 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • CHMI with 3D7 malaria
Record updated
27 December 2024

Who can take part

Age
18 years to 35 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Participant is aged ≥18 and ≤35 years and in good health
  • Rechallenge group only: participation in CoGA study, having received immunisation with 1x 50 GA2-infected MB, and protected during subsequent CHMI
  • Participant has adequate understanding of the procedures of the study and agrees to abide strictly thereby
  • Participant is able to communicate well with the investigator
  • Participant is available to attend all essential study visits
  • Participant agrees that his/her general practitioner (GP) will be informed about participation in the study
  • Participant agrees to refrain from blood donation to Sanquin or for other purposes. throughout the study period and for a defined period thereafter according to Sanquin guidelines
  • Participants of child bearing potential (i.e., have an uterus and are neither surgically sterilized nor post-menopausal) agree to use adequate contraception and to not breastfeed for the duration of study
  • Participant agrees to refrain from intensive physical exercise (disproportionate to the participants' usual daily activity or exercise routine) for twenty-one days following the immunization and during the malaria challenge period
  • Participant signs informed consent

Who cannot take part

  • Infection controls only: any history of malaria or previous participation in any malaria (vaccine) study or CHMI
  • Participation in any other clinical study assessing an investigational medical product in the 30 days prior to the start of the study or during the study period
  • A history of severe (allergic) reactions to mosquito bites
  • Any condition or situation that could influence the independent consent of participant (e.g. being a direct colleague or family member of study personnel)
  • Any other condition or situation that would, in the opinion of the investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol or would compromise the integrity of the data
  • Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions which could compromise the health of the participant during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following:; Body Mass Index (BMI) >35.0 kg/m2 at screening. b. An elevated risk of cardiovascular disease, defined as: i. An estimated ten-year risk of fatal cardiovascular disease of ≥5% at screening, as determined by the Systematic Coronary Risk Evaluation 2 (SCORE2) ; History, or evidence at screening, of clinically significant arrhythmia's, prolonged QT-interval or other clinically relevant ECG abnormalities; or iii. A positive family history of cardiac events in first- or second-degree relatives (according to the system used in medical genetics) <50 years old; Known functional asplenia, sickle cell trait/disease, thalassemia trait/disease or G6PD deficiency; History of epilepsy in the period of five years prior to study onset, even if no longer on medication; Positive HIV, HBV or HCV screening tests. e. Chronic use of i) immunosuppressive drugs, ii) antibiotics, iii) or other drugs that might have an influence on the immune system (excluding inhaled and topical corticosteroids and incidental use of oral anti-histamines), within three months prior to study onset or expected use of such during the study period; Skin disease affecting the site of administration in such a way that administration of mosquito bites is deemed impossible by investigator; History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past five years; Any history of treatment for severe psychiatric disease by a psychiatrist in the past year; History of drug or alcohol abuse interfering with normal social functioning in the period of one year prior to study onset, positive urine toxicology test for cocaine or amphetamines at screening
  • For participants of child bearing potential: breastfeeding, or positive serum pregnancy test prior to CHMI
  • Known hypersensitivity to or contra-indications for both atovaquone/proguanil or artemether/lumefantrine. QT prolonging drugs are only considered an exclusion criterion when QT prolongation is observed at the ECG at screening

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 35 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will assess the durability of protection of a single immunisation with the Genetically Attenuated Parasite 2 (GA2) against controlled human malaria infection by rechallenging previously immunised and protected participants from the CoGA study (NCT05468606)

The 2 groups in the trial

  • Rechallenge groupTreatment being tested

    Previous CoGA phase 1 study participants who were immunised with GA2 and who did not develop blood-stage malaria during CHMI (protected)

    Treatment: CHMI with 3D7 malaria

  • Infection control groupPlacebo, for comparison

    Malaria-naïve participants who have not been previously vaccinated with GA2

    Treatment: CHMI with 3D7 malaria

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Durability of Protection After Single Immunisation With Genetically Attenuated Plasmodium Falciparum ∆mei2 (GA2) Sporozoites - a Follow-up, Controlled Human Malaria Rechallenge Study
Criteria questions
Built from NCT06293339, who can take part
Record updated
27 December 2024